TY  - CONF

T1  - Phase I/II open label nonrandomized safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 immunotherapy in combination with PD-1 checkpoint blockade in intermediate-risk localized or locally advanced prostate cancer and advanced metastatic prostate cancer.

JO  - JOURNAL OF CLINICAL ONCOLOGY

PY  - 2020/01/01

AU  - Tuthill M

AU  - Cappuccini F

AU  - Bryant RJ

AU  - Poulton I

AU  - Pollock E

AU  - Carter L

AU  - Verrill C

AU  - Meier A

AU  - Schmidt G

AU  - Catto JWF

AU  - Evans T et al

ED  - 

VL  - 38

IS  - 15

Y2  - 2024/12/22

ER  -